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in the other two cirrhosis groups (p < 0.05). ALD-cir-
rhotic patients were more often male and smokers than
patients in the other two groups (p < 0.05). The three
cirrhosis groups did not diﬀer signiﬁcantly in the prev-
alence of obesity, hereditary predisposition to CAD,
cirrhosis complications or severity, or serum cholesterol
(p > 0.05 for all). In multivariate analysis, CAD was
found to be independently related to age (OR 1.1 per yr,
95% CI 1.04–1.2), ALD-cirrhosis (3.5, 95% CI 1.2–10.1),
and history of arterial hypertension (2.9, 95% CI
1.04–8.2).
Taken together, the ﬁndings of Kadayifci et al. [1]
and our results indicate that the prevalence of CAD is
higher in ALD- and NASH-cirrhosis compared to cir-
rhosis of other aetiologies. Both studies show that
CAD risk factors are more common in NASH-cirrhosis
than in cirrhosis of other aetiologies. These results sug-
gest that a more rigorous work-up for the diagnosis of
CAD may be indicated in patients with ALD- and
NASH-cirrhosis.
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Coronary artery disease in NASH-related cirrhosis
Table 1
Clinical characteristics and risk factors for coronary artery disease in
patients with ALD-cirrhosis, NASH-cirrhosis, and those with cirrhosis of
other etiologies.
NASH-
cirrhosis
(n = 22)
Alcoholic
cirrhosis
(n = 55)
Cirrhosis
of other
etiologies
(n = 50)
p-Value
Age (years) 63 (11) 58 (9) 53 (13) 0.001
Males 41% 75% 54% 0.011
Smoking 59% 80% 54% 0.014
Diabetes 41% 29% 16% 0.067
History of arterial
hypertension
52% 28% 12% 0.002
Obesity
(BMI > 30)
32% 13% 14% 0.104
Hereditary predisposition
for CAD
17% 7% 3% 0.214
Data are presented as mean (standard deviation) or percentage as
appropriate.
The p-value for ANOVA (age) or for chi-square testing (nominal
variables) for all three groups are reported.
SD, standard deviation; CAD, coronary artery disease.
Fig. 1. The prevalence of coronary artery disease in patients with ALD-
cirrhosis, NASH-cirrhosis, and in those with cirrhosis of other etiologies.
The p-value of chi-square test for all three groups is reported. ALD,
alcoholic liver disease; NASH, non-alcoholic steatohepatitis.
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We thank Drs. Kalaitzakis and Bjo¨rnsson [1] for their
interest in our paper [2] and for providing their data thatsupports our observation of a high prevalence of coro-
nary artery disease in patients with cirrhosis from non-
alcoholic steatohepatitis (NASH) compared to those
with cirrhosis of other aetiologies (COE). The authors
point to the absence of patients with alcoholic liver dis-
ease (ALD) among patients with COE in our study [2].
Indeed, our study diﬀered in its primary goal and se-
lected population from their recent publication [3] that
demonstrated a high prevalence of coronary artery dis-
ease among patients with predominantly alcoholic cir-
rhosis. The primary objective of our study was to
evaluate the relationship between NASH-related cirrho-
sis and coronary artery disease (CAD), compared with
other aetiologies of cirrhosis, in a population that had
undergone liver transplantation. The selection bias in
our age and sex-matched COE group, comprised of only
patients with viral hepatitis and cholestatic liver disease,
reﬂects the leading causes of liver cirrhosis in patients
undergoing liver transplantation at our center. ‘‘Pure”
alcoholic cirrhosis is an unusual indication for liver
transplantation at our center, although in a signiﬁcant
number of patients with hepatitis C, alcohol is consid-
ered a contributing factor to the development of
cirrhosis.
The data discussed in the letter by Kalaitzakis and
Bjo¨rnsson conﬁrms a high prevalence of CAD in patients
with NASH-related cirrhosis compared to cirrhosis sec-
ondary to other causes (excluding ALD) which supports
our observations [2]. However, their ﬁnding of a high
prevalence of CAD in ALD-cirrhosis is interesting and
unexpected, given the results of previous autopsy studies
[4,5] and the protective eﬀect of moderate alcohol con-
sumption on atherosclerosis suggested by many other
studies [6,7]. In their study population [1,3] the incidence
of important risk factors for CAD including age, smok-
ing, male gender, hypertension and diabetes were higher
in ALD-cirrhosis compared to their COE group. These
ﬁndings not only point to the consistent importance of
cardiovascular risk factors in determining the risk of
CAD in a group (ALD) conventionally considered to
be protected from CAD, but also raise the important
question of the relative contribution of alcohol and met-
abolic factors in the pathogenesis of cirrhosis in their pa-
tients etiologically classiﬁed as ALD.
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HCV genotype 3: An independent predictor of ﬁbrosis progression
in chronic hepatitis C
To the Editor:
The multi-centre study, by Bochud et al. [1], demon-
strating an association between hepatitis C virus (HCV)
genotype 3 and rapid progression of liver ﬁbrosis in
chronically infected patients, ampliﬁes the potential clin-
ical meaning of HCV genotypes, originally identiﬁed as
predictors of interferon therapy outcome. The report
from Switzerland corroborates the increasing evidence
that the natural history of hepatitis C may be also inﬂu-
enced by the genotype of HCV in addition to host and
environmental co-factors of morbidities. The road to
HCV genotype being a modiﬁer of the course of HCV
infection was opened a long time ago by HCV-1, shown
to be associated with rapid progression of recurrent hep-
atitis C in liver transplanted patients [2], and with in-
creased risk of hepatocellular carcinoma (HCC) in
patients with cirrhosis [3], and by HCV-2 associated
with ALT ﬂares that ultimately accelerate the course
of chronic hepatitis in untreated patients [4]. In this con-
text, the paper by Bochud et al. adds nicely to these ﬁnd-
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